AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

He has been the chair of the Department of Pharmacology and Chemical Biology since 2007. His main research interest is understanding the molecular basis of beta-lactamase-mediated antibiotic ...

AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...

Beta-lactamase inhibitors are designed to overcome a key resistance mechanism that allows pathogens to protect themselves from beta-lactams, one of the most commonly-used antibiotic classes.

Together, they’re being studied as a potential treatment option for serious bacterial infections caused by antibiotic-resistant gram-negative bacteria, including Extended Spectrum Beta-lactamase ...